Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Eptifibatide (Integrilin) Peptide
GP IIb/IIIa inhibitor cyclic peptide for ACS and PCI.
What is Eptifibatide (Integrilin)?
Eptifibatide (Integrilin) is a antiplatelet · cardiology peptide studied for acute coronary syndromes and pci. Below is an educational overview of Eptifibatide (Integrilin) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Integrilin
Acute coronary syndromes and PCI to prevent clot formation.
An IV drug that blocks the 'sticky receptor' on platelets so they cannot clump and form clots during heart procedures.
- •Bleeding (including at access sites)
- •Low platelets
- •Low blood pressure
- •Major bleeding
- •Severe thrombocytopenia
- •Active abnormal bleeding within 30 days
- •Stroke within 30 days
- •Severe uncontrolled hypertension
- •Severe kidney disease (dose adjust)
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Eptifibatide (Integrilin) Mechanism of Action
Cyclic heptapeptide derived from rattlesnake venom that reversibly blocks platelet glycoprotein IIb/IIIa receptors, preventing fibrinogen binding and platelet aggregation.
Eptifibatide (Integrilin) Research Areas & Benefits
Eptifibatide (Integrilin) Dosage & Common Research Protocols
180 mcg/kg IV bolus + 2 mcg/kg/min infusion.
Protocols summarized for educational reference from published research. Not dosing guidance.
Eptifibatide (Integrilin) Studies & Cited Research
PURSUIT trial
Reduced death/MI in non-ST-elevation ACS.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Eptifibatide (Integrilin) Side Effects & Safety Considerations
- •FDA-approved.
- •Bleeding risk; renal adjustment required.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.